6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy

Accreditation: 10.00 AMA PRA Category 1 Credit™ | 10.00 ABIM MOC II | 10.00 Nursing Contact Hours | 10.00 ACPE Pharmacy

Venue: Hyatt Regency San Francisco Downtown SOMA, 50 3rd Street, San Francisco, CA, United States

Start Date: September 11End Date: September 12, 2026

Faculty disclosures

Identification and mitigation of potential conflicts of interest

All conflict of interest has been identified and mitigated for individuals in control of contents.

Planning committee disclosure statement

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Co-Chairs

No, I have not had a financial relationship with an ineligible company within the past 24 months.

Awaiting faculty disclosure.

Associate Chairs

has a financial relationship (Speaker) with Natera; financial relationship (Speaker) with Biotheranostics; financial relationship (Speaker) with Pfizer/Seagen; financial relationship (Consultant) with Gilead Sciences; financial relationship (Consultant) with BAYER; financial relationship () with Astra Zenica; financial relationship (Consultant) with Astra Zenica; financial relationship (Speaker) with Puma Biotechnology.

Awaiting faculty disclosure.

has a financial relationship (Grant Or Contract) with Replimune; financial relationship (Grant Or Contract) with Inhibrx; financial relationship (Grant Or Contract) with Polaris; financial relationship (Grant Or Contract) with Prelude Therapeutics; financial relationship (Consultant) with Atheneum; financial relationship (Grant Or Contract) with Nested Therapeutics; financial relationship (Consultant) with ANCO; financial relationship (Consultant) with Clearview Health care; financial relationship (Consultant) with Iowa Oncology Society; financial relationship (Grant Or Contract) with Parabilis; financial relationship (Contractor) with Vivace Therapeutics.

Abstract Committee

has a financial relationship (Professional Service) with Incyte Inc.

Session Chairs

Awaiting faculty disclosure.

No, I have not had a financial relationship with an ineligible company within the past 24 months.

has a financial relationship (Ownership Interest) with Alessa Therapeutics, Kumquat Biosciences, Olema Pharmaceuticals, Onkure Therapeutics; financial relationship (Consultant) with Boehringer Ingelheim; financial relationship (Contractor) with Xynomic Pharmaceuticals, JS InnoPharm, GlaxoSmithKline (GSK) Pharmaceuticals, InventisBio, Amgen, Revolution Medicines, Scorpion Therapeutics, Nurix Therapeutics, MBrace Therapeutics, Novartis, Frontier Medicines, InventisBio, AbbVie, Corbus Pharmaceuticals, AstraZeneca, MacroGenics, Ensem Therapeutics, Zai Lab, Xadcera Biopharmaceutical, Vividion Therapeutics.

Key Note Presenter

Awaiting faculty disclosure.

Topic Presenters

Awaiting faculty disclosure.

No, I have not had a financial relationship with an ineligible company within the past 24 months.

Awaiting faculty disclosure.

has a financial relationship (Patent Beneficiary) with Bethyl; financial relationship (Consultant) with DAVA Oncology; financial relationship (Consultant) with MDOutlook; financial relationship (Consultant) with Merck; financial relationship (Patent Beneficiary) with Merck; financial relationship (Consultant) with Regeneron Pharmaceuticals.

Awaiting faculty disclosure.

has a financial relationship (Employee) with Florida Cancer Specialists & Research Institute (through April 2025); financial relationship (Contractor) with OncAdvisor; financial relationship (Contractor) with PrecisCa.

Awaiting faculty disclosure.

has a financial relationship (Grant Or Contract) with 858 Therapeutics.; financial relationship (Grant Or Contract) with AstraZenca; financial relationship (Advisor) with AstraZeneca; financial relationship (Grant Or Contract) with Debiopharm; financial relationship (Grant Or Contract) with Exelixis; financial relationship (Grant Or Contract) with Incyte,; financial relationship (Grant Or Contract) with Repare Therapeutics.

Awaiting faculty disclosure.

has a financial relationship (Professional Service) with AstraZeneca; financial relationship (Professional Service) with Pfizer; financial relationship (Professional Service) with Takeda; financial relationship (Consultant) with Genentech; financial relationship (Professional Service) with Merck; financial relationship (Professional Service) with Daiichi Sankyo; financial relationship (Professional Service) with Eli Lilly; financial relationship (Professional Service) with Carisma Therapeutics; financial relationship (Professional Service) with OBI Pharma; financial relationship (Professional Service) with Eisai; financial relationship (Professional Service) with Bristol Myers Squibb; financial relationship (Professional Service) with Gilead Sciences; financial relationship (Professional Service) with AnHeart Therapeutics; financial relationship (Professional Service) with Tolero Pharmaceuticals; financial relationship (Professional Service) with Phoenix Molecular Designs; financial relationship (Professional Service) with Phoenix Molecular Designs; financial relationship (Professional Service) with Bayer AG; financial relationship (Professional Service) with Carna Biosciences Inc.; financial relationship (Professional Service) with CytoDyn Inc.; financial relationship (Professional Service) with Genomic Health; financial relationship (Professional Service) with Lavender Health; financial relationship (Professional Service) with OncoCyte Corporation; financial relationship (Other) with Pear Bio; financial relationship (Professional Service) with Peptilogics; financial relationship (Professional Service) with Preferred Medicine; financial relationship (Professional Service) with Sysmex Corporation; financial relationship (Professional Service) with Unitech Medical Inc.; financial relationship (Professional Service) with Chugai Pharmaceutical Co., Ltd; financial relationship (Professional Service) with Kyowa Kirin Co; financial relationship (Professional Service) with Total Health Conferencing; financial relationship (Professional Service) with Puma Biotechnology; financial relationship (Professional Service) with Oncolys BioPharma; financial relationship (Professional Service) with ChemDiv Inc; financial relationship (Professional Service) with VITRAC Therapeutics, LLC; financial relationship (Professional Service) with Exact Sciences; financial relationship (Professional Service) with Medsir; financial relationship (Consultant) with PER.

has a financial relationship (Advisor) with Clarity Pharmaceuticals; financial relationship (Consultant) with GE Healthcare; financial relationship (Consultant) with Lantheus; financial relationship (Grant Or Contract) with Lilly; financial relationship (Consultant) with Lilly; financial relationship (Consultant) with Novartis; financial relationship (Grant Or Contract) with Novartis; financial relationship (Advisor) with Nucleus RadioPharma; financial relationship (Advisor) with RadioneticsOncology.

No, I have not had a financial relationship with an ineligible company within the past 24 months.

Awaiting faculty disclosure.